@NervgenP drug NVG-291 could reverse the damage caused by Alzheimer’s reports @DailyMailUK
bit.ly/2YgLFaR
#Alzheimers #neuroscience #Biotech
NervGen Pharma Corp.
627 posts
NervGen Pharma Corp.
@NervgenP
Restoring Life’s Potential by Enabling the Nervous System to Repair Itself after Neurologic Trauma and Disease
Joined May 2019
- The origins of @NervgenP described as "a story of tragedy, a hope and a dream, and one for which the end is yet to be written" says @NervGenP founder in new book by @jancavelle
00:00 - Check out @codi_darnell's latest 'Nerve Matters' article about erasing the stigma on mobility aids with her interview with Tara Merrill, at: bit.ly/31AwtTI #NerveMatters #MultipleSclerosis @NervgenP
- Our lead drug candidate, NVG-291, is a first-in-class therapeutic that has the potential to enable repair of the nervous system. It’s currently being evaluated in a Phase 1b/2a clinical trial for individuals with spinal cord injury. View our full video to learn more:
00:00 - NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating NVG-291 in spinal cord injury. Read more about the results: bit.ly/1b2aChronicCoh… #SCI #SpinalCordInjury #news
- NVG-291-R, developed by @NervgenP is focus of new animal stroke study, conducted by @uofcincy and @cwru which showed improved memory, motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset. bwnews.pr/3zOdtmV #ScienceTwitter
- NervGen today announced that it has completed enrollment in the chronic cohort of its Phase 1b/2a #SpinalCordInjury clinical trial for NVG-291 and initiated screening subjects for the subacute cohort of the study. nervgen.com/nervgen-comple… #news
- 𝗥𝗲𝗺𝗮𝗿𝗸𝗮𝗯𝗹𝗲 𝗣𝗲𝗼𝗽𝗹𝗲's @GuyKawasaki, interviews @cwru spinal cord injury researcher, 𝗗𝗿. 𝗝𝗲𝗿𝗿𝘆 𝗦𝗶𝗹𝘃𝗲𝗿, on his remarkable scientific journey. guykawasaki.com/dr-jerry-silve… @CWRUSOM @MaverixPe @ruffoloj @AndrewBellBNN @AbilityLab @youngcodling @DougRoland @X
00:00 - Advances in modern medicine allow for things once never thought possible, like the repair of nervous system damage. Watch the full video to learn more about the potential of NVG-291. #biotech #neuroscience #innovation vimeo.com/885838112?shar…
00:00 - "In early clinical trials with a drug candidate that may repair damaged nerves in spinal cord injuries, @NervgenP receives FDA Fast Track designation," reports @BIVnews. shorturl.at/bivwF #spinalcordinjury @AbilityLab @ruffoloj @MaverixPe
- We believe our lead drug candidate, NVG-291, has the potential to promote groundbreaking nervous system repair and functional recovery in #spinalcordinjuries, and possibly in other neurological diseases like #Stroke #Alzheimers or #MS. Watch the full video:
00:00 - #DYK: NervGen and Shirley Ryan AbilityLab are conducting a clinical trial in #SCI. Watch to learn more about our unique trial design using electrophysiology. bit.ly/NervGenBreakin… #spinalcordinjury #clinicaltrial #science
00:00 - NervGen Pharma Corp. is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of NVG-291 in individuals with spinal cord injury at the Shirley Ryan @AbilityLab in Chicago. Some of the eligibility requirements for this trial include: ▶ Age 18-75 ▶
00:00 - NervGen Pharma on track to complete enrollment, deliver data readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury:
